Compared to Estimates, McKesson (MCK) Q4 Earnings: A Look at Key Metrics

McKesson (MCK) reported $96.3 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 6%. EPS of $11.69 for the same period compares to $10.12 a year ago.The reported revenue represents a surprise of -5.52% over the Zacks Consensus Estimate of $101.92 billion. With the consensus EPS estimate being $11.56, the EPS surprise was +1.14%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how McKesson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenue- North American Pharmaceutical: $79.12 billion versus the three-analyst average estimate of $84.12 billion. The reported number represents a year-over-year change of -4.9%.Revenue- Medical-Surgical Solutions: $2.87 billion versus the three-analyst average estimate of $2.94 billion. The reported number represents a year-over-year change of +0.5%.Revenue- Prescription Technology Solutions: $1.5 billion versus the three-analyst average estimate of $1.47 billion. The reported number represents a year-over-year change of +11.7%.Revenue- Oncology & Multispecialty: $12.71 billion versus $12.69 billion estimated by three analysts on average.Revenue- Other: $101 million versus $69.63 million estimated by two analysts on average.Adjusted Operating Profit- Oncology & Multispecialty: $385 million compared to the $392.25 million average estimate based on three analysts.Adjusted Operating Profit- Medical-Surgical Solutions: $271 million compared to the $284.53 million average estimate based on three analysts.Adjusted Operating Profit- North American Pharmaceutical: $980 million versus $991.34 million estimated by three analysts on average.Adjusted Operating Profit- Prescription Technology Solutions: $322 million compared to the $310.2 million average estimate based on three analysts.Adjusted Operating Profit- Corporate: $-209 million versus the two-analyst average estimate of $-197.04 million.Adjusted Operating Profit- Other: $8 million compared to the $4.09 million average estimate based on two analysts.View all Key Company Metrics for McKesson here>>>Shares of McKesson have returned -14.6% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.See Stocks Now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks